dotarem multidose 0,5 mmol/ml roztwór do wstrzykiwań
guerbet - acidum gadotericum - roztwór do wstrzykiwań - 0,5 mmol/ml
dotarem 0,5 mmol/ml roztwór do wstrzykiwań w ampułko-strzykawce
guerbet - acidum gadotericum - roztwór do wstrzykiwań w ampułko-strzykawce - 0,5 mmol/ml
cyclolux 0,5 mmol/ml roztwór do wstrzykiwań
sanochemia pharmazeutica gmbh - acidum gadotericum - roztwór do wstrzykiwań - 0,5 mmol/ml
cyclolux multidose 0,5 mmol/ml roztwór do wstrzykiwań
sanochemia pharmazeutica gmbh - acidum gadotericum - roztwór do wstrzykiwań - 0,5 mmol/ml
gadovist 1,0 604,72 mg/ml roztwór do wstrzykiwań
bayer ag - gadobutrolum - roztwór do wstrzykiwań - 604,72 mg/ml
primovist 0,25 mmol/ml roztwór do wstrzykiwań
bayer ag - gadoksetynian disodowy - roztwór do wstrzykiwań - 0,25 mmol/ml
tysabri
biogen netherlands b.v. - natalizumab - stwardnienie rozsiane - selektywne leki immunosupresyjne - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod mylan
mylan ireland limited - fingolimod jest chlorowodorek - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
gadoteric acid farmak 0,5 mmol/ml roztwór do wstrzykiwań
farmak international sp. z o.o. - acidum gadotericum - roztwór do wstrzykiwań - 0,5 mmol/ml